of them being still active on the trial at the time of the presentation. The enrollment of the randomized open label Phase II FORTIS trial has successfully been completed. The trial evaluates iadademstat as a monotherapy in relapsed/refractory myelodysplastic syndrome (MDS) patients who are unresponsive or intolerant to standard of care hypomethylating agents. Enrollment of the 50 patient cohort was completed in December 2022.

Original Release: https://www.globenewswire.com/news-release/2023/02/17/2610827/0/en/ORYZON-Reports-Financial-Results-and-Corporate-Update-for-Quarter-Ended-December-31-2022.html

Previous Post
CEO Caught in Major Lie, Embarrassing Decades-Old Requirement Used as Inspiration.
Next Post
CEO Admits to Dishonest Report, Harshly Rejects Billie Jean King’s Advice